gci

ZO Skin Health Acquires ReFissa Hyperpigmentation Tech from Suneva Medical

Contact Author
Close
Fill out my online form.

ZO Skin Health, Inc. has announced the acquisition of ReFissa and its generic equivalent tretinion—a derivative of vitamin A—from Suneva Medical.

The financial terms of the acquisition have not been disclosed at this time.

Zein Obagi, MD, founder and medical director of ZO Skin Health, said, “Vitamin A has always been a critical component of my treatment protocol for my patients... By acquiring ReFissa, we are able to offer to all of our physician partners a product with superior anti-aging and skin tone benefits so they can continue to prescribe in accordance with my protocols.”

Mark Williams, president, CEO and general counsel for ZO Skin Health, stated, “This is a strategic acquisition for us. It allows the company to complete founder Dr. Zein Obagi’s protocols, specifically those for hyperpigmentation. ReFissa is a best-in-class product that will deliver superior results and complement our existing portfolio of products.”